Explore our curated collection of technical analyses and commercial scale-up strategies specifically focused on Aeromonas caviae B18. These insights are designed to support R&D and procurement teams in optimizing their supply chains.
Novel Aeromonas caviae B18 strain enables high-purity chiral intermediate production with reduced costs and simplified downstream processing for pharma.